Literature DB >> 7910951

Prolonged paralysis due to nondepolarizing neuromuscular blocking agents and corticosteroids.

R J Barohn1, C E Jackson, S J Rogers, L W Ridings, A L McVey.   

Abstract

The long-term use of nondepolarizing neuromuscular blocking agents (ND-NMBA) has recently been implicated as a cause of prolonged muscle weakness, although the site of the lesion and the predisposing factors have been unclear. We report 3 patients (age 37-52 years) with acute respiratory insufficiency who developed prolonged weakness following the discontinuation of ND-NMBAs. Two patients also received intravenous corticosteroids. Renal function was normal but hepatic function was impaired in all patients, and all had acidosis. Electrophysiologic studies revealed low amplitude compound motor action potentials, normal sensory studies, and fibrillations. Repetitive stimulation at 2 Hz showed a decremental response in 2 patients. The serum vecuronium level measured in 1 patient 14 days after the drug had been discontinued was 172 ng/mL. A muscle biopsy in this patient showed loss of thick, myosin filaments. The weakness in these patients is due to pathology at both the neuromuscular junction (most likely due to ND-NMBA) and muscle (most likely due to corticosteroids). Hepatic dysfunction and acidosis are contributing risk factors.

Entities:  

Mesh:

Substances:

Year:  1994        PMID: 7910951     DOI: 10.1002/mus.880170613

Source DB:  PubMed          Journal:  Muscle Nerve        ISSN: 0148-639X            Impact factor:   3.217


  13 in total

Review 1.  Neuromuscular transmission and its pharmacological blockade. Part 4: Use of relaxants in paediatric and elderly patients, in obstetrics, and in the intensive care unit.

Authors:  L H Booij
Journal:  Pharm World Sci       Date:  1997-02

Review 2.  Critical illness neuromuscular disease: clinical, electrophysiological, and prognostic aspects.

Authors:  B Tabarki; A Coffiniéres; P Van Den Bergh; G Huault; P Landrieu; G Sébire
Journal:  Arch Dis Child       Date:  2002-02       Impact factor: 3.791

Review 3.  [Intensive care unit acquired weakness. Pathogenesis, treatment, rehabilitation and outcome].

Authors:  M Ponfick; K Bösl; J Lüdemann-Podubecka; G Neumann; M Pohl; D A Nowak; H-J Gdynia
Journal:  Nervenarzt       Date:  2014-02       Impact factor: 1.214

4.  Risk factors for critical illness polyneuromyopathy.

Authors:  J Bednarík; P Vondracek; L Dusek; E Moravcova; I Cundrle
Journal:  J Neurol       Date:  2005-03-30       Impact factor: 4.849

Review 5.  The Sick and the Weak: Neuropathies/Myopathies in the Critically Ill.

Authors:  O Friedrich; M B Reid; G Van den Berghe; I Vanhorebeek; G Hermans; M M Rich; L Larsson
Journal:  Physiol Rev       Date:  2015-07       Impact factor: 37.312

Review 6.  Toxic myopathies.

Authors:  Mamatha Pasnoor; Richard J Barohn; Mazen M Dimachkie
Journal:  Neurol Clin       Date:  2014-08       Impact factor: 3.806

7.  Critical illness polyneuromyopathy: the electrophysiological components of a complex entity.

Authors:  Josef Bednarik; Zdenek Lukas; Petr Vondracek
Journal:  Intensive Care Med       Date:  2003-07-17       Impact factor: 17.440

8.  Sub-tenon atracurium injection in rabbit eyes;a histopathologic study.

Authors:  Nafiseh Hashemi; Setareh Shomali; Hamid Heyrani-Moghaddam; Shahram Amini; Shahrokh Izadi
Journal:  J Ophthalmic Vis Res       Date:  2009-01

Review 9.  Pharmacology, selection and complications associated with neuromuscular blocking drugs in ICU patients.

Authors:  R C Prielipp
Journal:  Yale J Biol Med       Date:  1998 Nov-Dec

Review 10.  Clinical review: Critical illness polyneuropathy and myopathy.

Authors:  Greet Hermans; Bernard De Jonghe; Frans Bruyninckx; Greet Van den Berghe
Journal:  Crit Care       Date:  2008-11-25       Impact factor: 9.097

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.